Bavarian Nordic A/S (OMX:BAVA) has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 2.5 million doses of liquid-frozen Jynneos vaccine.
FDA first approved Jynneos, a non-replicating smallpox and monkeypox vaccine, in 2019.
It continues to be the only FDA-approved vaccine indicated for monkeypox.
The company will begin deliveries in the recent contract in the fourth quarter of 2022 and continue into early 2023.
In May, Bavarian Nordic announced that it had secured a separate BARDA contract worth $119 million to convert bulk vaccine into freeze-dried doses of Jynneos vaccine.
In all, the company will supply a total of 4.4 million doses to the U.S. in 2022 and 2023.
The company’s share price increased 3.89% to 243.00 Danish Krone.
Earlier this week, the U.S. Department of Health and Human Services (HHS) announced an updated nationwide monkeypox vaccination strategy that will focus on those most vulnerable to infection. The plan is to prioritize vaccination in areas with the highest numbers of cases.
There are currently confirmed monkeypox infections in more than 30 U.S. states.
“The monkeypox outbreak continues to develop at an unprecedented rate, and we applaud the U.S. government’s decision to prioritize the supply of our vaccine to enable broader access for those at risk of infections,” said Paul Chaplin, President and CEO of Bavarian Nordic, in a news release. “The foresight of the U.S. government to support Bavarian Nordic in the development of Jynneos and establishing the manufacturing infrastructure has not only benefited the United States but also global supply when, unfortunately, most other governments failed to foresee the threat. We are proud to be able to assist our partner in fulfilling this important task through our long-standing collaboration to develop and manufacture a vaccine, which can be administered safely and help mitigate the health burden from monkeypox.”